Treatment of advanced melanoma - A changing landscape

Imagem de Miniatura
Arquivos
art_HEPNER_Treatment_of_advanced_melanoma_A_changing_landscape_2017.PDF (196.58 KB)
Citações na Scopus
19
Tipo de produção
article
Data de publicação
2017
Editora
ASSOC MEDICA BRASILEIRA
DOI
Indexadores
SciELO
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Autores
HEPNER, Adriana
SALGUES, Alessandra
ANJOS, Carlos A. dos
GARICOCHEA, Bernardo
SHOUSHTARI, Alexander N.
POSTOW, Michael A.
FERNANDES, Gustavo S.
Autor de Grupo de pesquisa
Editores
Coordenadores
Organizadores
Citação
REVISTA DA ASSOCIACAO MEDICA BRASILEIRA, v.63, n.9, p.814-823, 2017
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Following decades of relative ostracism, advances in the treatment of melanoma have brought a new reality for patients, physicians and researchers. While antibodies targeting molecules involved in the modulation of the interaction between melanoma and immune cells changed the meaning of the term ""cancer immunotherapy,"" a better characterization of the molecular aberrations involved in melanoma carcinogenesis prompted the development of inhibitors of the mitogen-activated protein kinase pathway (MAPK) that also led to significant improvements both in response rates and survival. As a result, new drugs have been approved for clinical use in the United States and Europe, including the immune-checkpoint blockers ipilmumab, pembrolizumab and nivolumab, the oncolytic herpesvirus talimogene laherparepvec, and the targeted-agents vemurafenib, dabrafenib, cobimetinib and trametinib. In this article, we review the results of studies that brought new approaches to the bedside and discuss how these developments are being incorporated into the care of patients in Brazil.
Palavras-chave
melanoma, anti-PD1, anti-CTLA4, BRAF, MEK
URI
https://observatorio.fm.usp.br/handle/OPI/25717
Referências
  1. American Cancer Society, CANC FACTS FIG 2016
  2. Andtbacka RHI, 2015, J CLIN ONCOL, V33, P2780, DOI 10.1200/JCO.2014.58.3377
  3. Ascierto PA, 2016, ANN OF ONCOLOGY
  4. Ascierto PA, 2016, LANCET ONCOL, V17, P1248, DOI 10.1016/S1470-2045(16)30122-X
  5. Atkins MB, 2000, CANCER J SCI AM, V6, pS11
  6. Bhatia S, 2009, ONCOLOGY-NY, V23, P488
  7. Carvajal RD, 2011, JAMA-J AM MED ASSOC, V305, P2327, DOI 10.1001/jama.2011.746
  8. Chen LP, 2013, NAT REV IMMUNOL, V13, P227, DOI 10.1038/nri3405
  9. Daud A, 2016, J CLIN ONCOL, V34, DOI 10.1200/JCO.2016.34.15_suppl.9513
  10. Dummer R, 2015, ANN ONCOL, V26, pV126, DOI 10.1093/annonc/mdv297
  11. Dummer R, 2016, J CLIN ONCOL, V34, DOI 10.1200/JCO.2016.34.15_supll.9500
  12. Erdei E, 2010, EXPERT REV ANTICANC, V10, P1811, DOI [10.1586/era.10.170, 10.1586/ERA.10.170]
  13. Flaherty K, 2016, ASCO M, P9502
  14. Flaherty KT, 2012, NEW ENGL J MED, V367, P107, DOI [10.1056/NEJMoa1203421, 10.1056/NEJMoa1210093]
  15. Flaherty KT, 2010, J CLIN ONCOL S, V28, p613s
  16. Grob JJ, 2015, LANCET ONCOL, V16, P1389, DOI 10.1016/S1470-2045(15)00087-X
  17. Guo J, 2011, J CLIN ONCOL, V29, P2904, DOI 10.1200/JCO.2010.33.9275
  18. Hamid O, 2015, 12 C SOC MEL RES 201
  19. Hauschild A, 2013, ASCO M, V31, P9013
  20. Hauschild A, 2012, LANCET, V380, P358, DOI 10.1016/S0140-6736(12)60868-X
  21. Hennecke J, 2001, CELL, V104, P1, DOI 10.1016/S0092-8674(01)00185-4
  22. Hodi FS, 2013, J CLIN ONCOL, V31, P3182, DOI 10.1200/JCO.2012.47.7836
  23. Hodi FS, 2010, NEW ENGL J MED, V363, P711, DOI 10.1056/NEJMoa1003466
  24. Hodi FS, 2016, CANC RES S, V76
  25. INCA. Instituto Nacional do Cancer, 2016, EST 2016 INC D0 CANC
  26. Kim KB, 2008, BRIT J CANCER, V99, P734, DOI 10.1038/sj.bjc.6604482
  27. Kim KB, 2013, J CLIN ONCOL, V31, P482, DOI 10.1200/JCO.2012.43.5966
  28. Larkin J, 2015, NEW ENGL J MED, V373, P23, DOI 10.1056/NEJMoa1504030
  29. Long GV, 2016, J CLIN ONCOL, V34, DOI 10.1200/JCO.2016.34.15_supll.9506
  30. Long GV, 2014, J CLIN ONCOL, V32
  31. Long GV, 2011, J CLIN ONCOL, V29, P1239, DOI 10.1200/JCO.2010.32.4327
  32. Long GV, 2016, ASCO M ABSTR S15, V34, P9568
  33. McArthur GA, 2014, LANCET ONCOL, V15, P323, DOI 10.1016/S1470-2045(14)70012-9
  34. Mellman I, 2011, NATURE, V480, P480, DOI 10.1038/nature10673
  35. Postow MA, 2015, NEW ENGL J MED, V372, P2006, DOI 10.1056/NEJMoa1414428
  36. Puzanov I, 2016, J CLIN ONCOL, V34, P2619, DOI 10.1200/JCO.2016.67.1529
  37. Ribas A, 2016, ASCO M, V34, P3014
  38. Ribas A, 2016, JAMA-J AM MED ASSOC, V315, P1600, DOI 10.1001/jama.2016.4059
  39. Ribas A, 2015, LANCET ONCOL, V16, P908, DOI 10.1016/S1470-2045(15)00083-2
  40. Rizos H, 2014, CLIN CANCER RES, V20, P1965, DOI 10.1158/1078-0432.CCR-13-3122
  41. Robert C, 2016, ANN ONCOL, V27, DOI 10.1093/annonc/mdw435.37
  42. Robert C, 2015, NEW ENGL J MED, V372, P30, DOI 10.1056/NEJMoa1412690
  43. Schacter J, 2016, J CLIN ONCOL, V34
  44. Schadendorf D, 2015, J CLIN ONCOL, V33, P1889, DOI 10.1200/JCO.2014.56.2736
  45. Schmerling RA, 2011, REV PANAM SALUD PUBL, V30, P431, DOI 10.1590/S1020-49892011001100005
  46. Topalian SL, 2014, J CLIN ONCOL, V32, P1020, DOI 10.1200/JCO.2013.53.0105
  47. Weber JS, 2015, LANCET ONCOL, V16, P375, DOI 10.1016/S1470-2045(15)70076-8
  48. Wolchok JD, 2016, J CLIN ONCOL, V34, DOI 10.1200/JCO.2016.34.15_supll.9505
  49. Yajima I, 2012, DERMAT RES PRACT, DOI 10.1155/2012/354191
  50. 2015, CELL, V161, P1681, DOI 10.1016/J.CELL.2015.05.044

Coleções
Artigos e Materiais de Revistas Científicas - HC/ICESP
Artigos e Materiais de Revistas Científicas - ODS/03